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Abstract
PDZ-GEF1 (RA-GEF/nRapGEP/CNrasGEF) is a guanine nucleotide exchange factor (GEF) characterised by the presence of a PSD-95/
DlgA/ZO-1 (PDZ) domain, a Ras-association (RA) domain and a region related to a cyclic nucleotide binding domain (RCBD). These
domains are in addition to a Ras exchange motif (REM) and GEF domain characteristic for GEFs for Ras-like small GTPases. PDZ-GEF1
efficiently exchanges nucleotides of both Rap1 and Rap2, but has also been implicated in mediating cAMP-induced Ras activation through
binding of cAMP to the RCBD. Here we describe a new family member, PDZ-GEF2, of which we isolated two splice variants (PDZ-GEF2A
and 2B). PDZ-GEF2 contains, in addition to the domains characteristic for PDZ-GEF1, a second, less conserved RCBD at the N-terminus.
PDZ-GEF2 is also specific for both Rap1 and Rap2. We further investigated the possibility that PDZ-GEF2, like PDZ-GEF1, is a cAMP-
responsive GEF for Ras. However, in contrast to previous results, we did not find any effect of either PDZ-GEF1 or PDZ-GEF2 on Ras in the
absence or presence of cAMP. Moreover, affinity measurements by isothermic calorimetry showed that the RCBD of PDZ-GEF1 does not
bind cAMP with a physiologically relevant affinity. We conclude that both PDZ-GEF1 and 2 are specific for Rap1 and Rap2 and
unresponsive to cAMP and various other nucleotides.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Rap1 is a Ras-like small GTPase that may function in a
variety of different cellular processes, like integrin-mediated
cell adhesion, cell proliferation and differentiation, and
platelet activation [1,2]. A variety of extracellular stimuli
(e.g. growth hormones and cytokines) are able to activate
Rap1 [3]. Activation is mediated by guanine nucleotide
exchange factors (GEFs) that substitute the bound GDP for
GTP. Four types of Rap-specific GEFs have been identified,
some of which are regulated directly by second messengers.
CD-GEF1 and 3 are presumably regulated by calcium and
diacylglycerol (DAG), since both contain calcium and DAG-
binding domains [4–6]. Epac1 and 2, are GEFs directly
regulated by cAMP through binding of cAMP to a cAMP-
binding domain very similar to those present in the regulatory
domain of protein kinase A (PKA) [7–9]. C3G is a GEF that
is activated by receptor tyrosine kinases by binding to the
activated receptor through the adapter protein Crk [10,11].
The most recently identified GEF for Rap1 is PDZ-GEF1.
PDZ-GEF1 (also called RA-GEF-1, nRap GEP or
CNrasGEF) [12–15] is characterised by the presence of a
PSD-95/DlgA/ZO-1 (PDZ) domain, a Ras-association (RA)
domain and a region related to a cyclic nucleotide binding
domain (RCBD). In addition, it contains a Ras exchange
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motif (REM) and a GEF domain characteristic for GEFs for
Ras-like small GTPases. At the C-terminus of PDZ-GEF1, a
proline-rich region and a PDZ-binding motif are found. The
GEF domain of PDZ-GEF1 efficiently exchanges nucleo-
tides of both Rap1 and its close relative Rap2. The various
other domains likely play a role in the regulation of activity
or localisation of the protein.
The RA domain interacts with active Rap1 and also
contributes to membrane localisation of PDZ-GEF1 [16].
This domain may function in a positive feedback loop. The
PDZ-binding motif was found to interact with the scaffold-
ing protein S-SCAM (or MAGI-2) and MAGI-1 [14,17].
These scaffolding proteins are localised to synaptic struc-
tures and cell adherens junctions, respectively, implying that
PDZ-GEF1 might be localised there as well. Indeed, PDZ-
GEF1 has been found to co-localise with h-catenin and ZO-
1 at sites of cell–cell contact [18]. Finally, the PDZ domain
also plays a role in localisation, as deletion of a critical part
of the PDZ domain affects plasma membrane localisation
[15]. PDZ domains are protein–protein interaction domains,
usually interacting with the C-terminus of membrane pro-
teins containing a PDZ-binding motif, but for PDZ-GEF1
the partner of the PDZ domain has not yet been identified.
The stability of the PDZ-GEF protein is regulated by the E3
ligase Nedd4, which can bind to the proline-rich regions of
PDZ-GEF1. Nedd4 ubiquitinates PDZ-GEF1, leading to
degradation by the proteasome [19]. The RCDB of PDZ-
GEF1 is closely related to the cAMP-binding domain of
Epac. However, it lacks several critical residues involved in
cAMP binding. The function of this domain in the regu-
lation of PDZ-GEF1 with respect to GEF activity towards
Rap1 and Rap2 is still unclear, although deletion of the
RCBD results in vitro in more GEF activity [12]. Intrigu-
ingly, Pham et al. [15] reported that CNrasGEF, a protein
identical to PDZ-GEF1, is a cAMP-responsive GEF for the
small GTPase Ras.
We describe here the identification of PDZ-GEF2, a close
relative of PDZ-GEF1, which is also a GEF specific for
Rap1 and Rap2. No activity towards Ras was observed in
vitro. PDZ-GEF2 contains in comparison to PDZ-GEF1 an
extra, less conserved, RCBD at the N-terminus. We identi-
fied two splice variants of PDZ-GEF2 (2A and 2B).
Recently, a third splice variant of PDZ-GEF2 (RA-GEF-2)
was described [20]. In addition, we characterised both PDZ-
GEF1 and 2 in further detail and found no evidence for
cAMP binding by the RCBD, nor exchange activity towards
Ras. We conclude that both PDZ-GEFs are specific for Rap1
and Rap2 and unresponsive to cAMP.
2. Materials and methods
2.1. Cloning of PDZ-GEF2A and 2B
Open reading frames (ORFs) of human PDZ-GEF2A and
2Bwere predicted on the basis of ESTs, using a blast program
(NCBI) [21], and on basis of intron/exon predictions for the
genomic sequence by NIX analysis (http://www.hgmp.mrc.
ac.uk/). Total RNA was isolated from umbilical cord tissue
and Jurkat T cells using RNAzol, according to the manu-
facturer’s protocol (Campro Scientific). cDNA was gener-
ated from these total RNA extracts with poly-dT primers,
using the Promega reverse transcription system. Three sets of
primers were designed to amplify the whole coding se-
quence: N-for (gtcgacGAACTCACCCGTGGACC) and N-
rev (TAAGTTGGATCCACGATGG) for the N-terminal
part, M-for (gtcgacAGAGGGAGAAATTGTTATGG) and
M-rev (gcggccgcAAGGTACCATATGCAGG) for the mid-
dle part, C-for (TTGGGAAAAGTTACCAAGC) and CA-
rev (gcggccgcAAATAGGTCATCCAAAGG) and CB-rev
(gcggccgcTTCATCAGAGTGTCTTCC), respectively, for
the C-terminal part of PDZ-GEF2A and 2B. The PCR pro-
ducts were subcloned in pGEM-T vectors (Promega) and
sequenced. Full-length PDZ-GEF2A, PDZ-GEF2A-DRCBD
(amino acid 393–1601) and PDZ-GEF2-DC (amino acid 1–
1141) were cloned using the unique internal BamHI and
BglII sites and the by PCR created SalI and NotI sites. The
RCBD of PDZ-GEF2 (amino acid 1–417) was subcloned in
the SalI and BamHI sites of pBluesript (Stratagene), using
the by PCR introduced SalI site and a PDZ-GEF2 internal
BclI site. For expression in mammalian cells, these construct
were subcloned in the SalI and NotI sites of pMT2-HA, in
frame with the HA-tag. For protein purification PDZ-GEF2-
DC, PDZ-GEF2-DRCBD-DC (amino acid 393–1141) and
the RCBD of PDZ-GEF2 were cloned in the XhoI and NotI
sites of pGEX-4T3 (Pharmacia) in frame with the GST-tag,
using the SalI and NotI sites.
2.2. Protein expression and purification
GST-tagged PDZ-GEF proteins were expressed in E. coli
BL21 by induction with 0.1 mM IPTG for 20 h at room
temperature. The bacteria were collected and lysed in ice-
cold phosphate-buffered saline containing 0.5% Triton X-
100 and protease inhibitors and sonicated six times for 20 s.
Lysates were cleared by centrifugation at 10,000 g and
glycerol was added at 10% final concentration. The GST
fusion proteins were purified by incubation of the lysate
with glutathione-agarose beads (Sigma) and eluted with
10mM glutathione in buffer containing 50 mM Tris, pH
7.5; 100 mM NaCl; 10% glycerol and 2mM MgCl2.
Purification of small GTPases and the proteins used for
the experiment shown in Fig. 5 were described elsewhere
[22,23].
2.3. Cell culture, transfection and stable cell lines
NIH-3T3-A14 cells and Rat1 fibroblasts were cultured
in DMEM, supplemented with 10% fetal bovine serum
and 0.05% glutamine. Cells were transfected, using the
calcium-phosphate precipitation method [24]. Stable cell
lines were made by transfecting NIH-3T3-A14 cells and
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Rat1 cells with the vector pBabe, which contains the
puromycin resistance gene, or with pBabe together with
a HA-tagged PDZ-GEF construct (ratio 1:10). Two days
after transfection, medium containing 2 Ag/ml puromycin
(Sigma) was added. Single colonies were picked and
tested for expression. Monoclonal cell lines were made
from clones expressing full-length PDZ-GEF1, by limiting
dilution.
2.4. Northern and Western blotting
A multiple tissue northern with poly(A) RNA from
various human tissues (CLONTECH) was probed, accord-
ing to the protocol of the manufacturer, with a 32P-radio-
active labeled PDZ-GEF2 probe, coding for the sequence
spanning the GEF domain. Western blotting of total lysates
and protein samples, isolated with an activation specific
probe, was performed using polyvinylidene difluoride
membranes (NENk). Antibodies used to detect the pro-
teins were anti HA (12CA5 and sc-805, Santa Cruz), anti
Rap-1/Krev-1 (sc-65, Santa Cruz), anti Ras (Transduction
Laboratories) and anti phospho-CREB (Ser133, Cell Sig-
naling).
2.5. In vitro activation of small GTPases
GEF activity was measured in vitro as described in Ref.
[22]. Briefly, 100–400 nM of the purified small GTPase
loaded with fluorescent labeled 2V,3V-bis(O)-N-methylanthar-
anoloyl-guanosinediphosphate (mantGDP), was incubated
with 20–200 nM of purified GEF in the presence of excess
unlabeled GDP. Nucleotides were added at 100 AM final
concentrations. Release of mantGDP was measured in real
time as a decrease in fluorescence. Reaction rates were
calculated from fitted, single exponential curves. Cell
extracts were made as follows. Cells were sheared 20 times
through a 23 gauge needle in buffer containing 50 mM Tris,
pH 7.5; 100 mM NaCl; 10% glycerol; 2mM MgCl2. Lysates
were cleared by centrifugation at 10,000 g and molecules
smaller than 3 kDa were collected by spinning the lysates
through a 3 kDa size column (Centricon).
2.6. In vivo activation of small GTPases
NIH-3T3-A14 cells were transiently transfected with
HA-tagged PDZ-GEF constructs in combination with HA-
tagged Rap1 (cloned in pMT2-HA vector). Alternatively,
cell lines stably expressing HA-tagged PDZ-GEF1 or PDZ-
GEF2-DC were used. For the experiment shown in Fig. 3E,
cells were serum-starved for 20 h prior to lysis. Cells were
stimulated with forskolin (20 AM) in combination with
IBMX (1 mM) for 5 or 15 min or with EGF (25 ng/ml)
for 2 or 5 min. GTP-bound Rap was isolated using purified
GST-RalGDS-RBD protein as an activation-specific probe
as described [25] and for GTP-bound Ras purified GST-Raf-
RBD was used [26].
2.7. Isothermal titration calorimetry (ITC) measurements
ITC measurements were done for cAMP binding to the
RCBD domain of PDZ-GEF1 (amino acid 1–268) and to
the cAMP-binding domain of Epac1. The isolated domains
(cleaved from the GST-tag) were thermostatted in the cell of
the apparatus to 25 jC and cAMP was injected from a
syringe, in 40 steps, up to a 2–4-fold molar excess. The cell
contains 1.36 ml protein solution (0.63 mM PDZ-GEF1-
RCBD or 66.7 AM Epac1 cAMP-binding domain) in buffer
containing 50 mM Tris–HCl pH 7.6; 50 mM NaCl; 5%
glycerol and 5 mM DTE. Typically, cAMP was added in
steps of 6 Al every 4 min. The data were analysed using the
manufacturers software.
3. Results
3.1. Cloning of PDZ-GEF2A and 2B
The human PDZ-GEF2 gene was identified in a genomic
sequence of chromosome 5 by homology searches with
PDZ-GEF1 [12]. The intron/exon structure was predicted
and primers were designed to amplify cDNA from human
umbilical cord cDNA and from Jurkat T cell cDNA. Two
different mRNAs were identified, which differ in their C-
terminus due to alternative splicing. Like PDZ-GEF1
[12,17], PDZ-GEF2 is rather ubiquitously expressed (Fig.
1E). The transcript is about 9 kb and slightly larger than the
PDZ-GEF1 transcript. Using a probe specific for PDZ-
GEF2B mRNA we did not obtain a clear signal, indicating
that the expression of this splice isoform is low or restricted.
PDZ-GEF2A encodes a protein of 1601 amino acids,
whereas PDZ-GEF2B encodes a protein of 1391 amino
acids. The two proteins differ after amino acid residue
1249. PDZ-GEF2A is most homologous to PDZ-GEF1,
with all the domains conserved. PDZ-GEF2B lacks the C-
terminal proline-rich sequences and the PDZ binding motif,
which are replaced by a sequence with no apparent homol-
ogy (Fig. 1A and B). Unlike PDZ-GEF1, PDZ-GEF2
contains an additional, N-terminal domain, which is dis-
tantly related to the RCBD (Fig. 1D). This domain is also
present in the single PDZ-GEF from C. elegans. This
situation is reminiscent to that for Epac, in that Epac1
contains a single and Epac2 a double cAMP-binding motif
(Fig. 1A).
3.2. PDZ-GEF2 specifically activates both Rap1 and Rap2
in vitro
To investigate the specificity of PDZ-GEF2 in vitro, a
GST fusion protein named PDZ-GEF2-DRCBD-DC (Fig.
3A) was purified. This PDZ-GEF2 fusion protein lacks
both the N-terminus, including the RCBD domains (1–
391) and the C-terminus (1142–1601). For comparison,
we used a similar construct for PDZ-GEF1 [12]. The
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Fig. 1. PDZ-GEF organisation. (A) Domain organisation of PDZ-GEFs in comparison to Epac. The arrow with amino acid number 1249 indicates the site from
which PDZ-GEF2A and 2B differ. Extra or deleted exons, compared to PDZ-GEF2A are indicated with amino acid counts in PDZ-GEF1 and RA-GEF-2, a
sequence recently published by Gao et al. [20]. P stands for proline-rich region and PBM stands for PDZ binding motif. (B) Complete amino acid sequence of
PDZ-GEF2A and 2B. The C-terminal ends where they differ are given separately, indicated by ‘2A’ and ‘2B’. Domains are lifted out with grey boxes. Sites
where RA-GEF-2 has small extra exons are indicated with arrowheads, and the exon that is not present in RA-GEF-2 is in the PDZ-GEF2A C-terminal part
shown by a box with dashed sites. (C) Alignment of the RCBD of PDZ-GEFs from different species and the cAMP-binding domain of Epac1 and PKA.
Identical amino acids are in a grey background. Amino acids in PKA that are involved in cAMP binding are indicated with arrows. (D) Alignment of the less
conserved second RCBD domain of human PDZ-GEF2 and C. elegans PDZ-GEF with part of the RCBD of human PDZ-GEF1. (E) Tissue distribution of
PDZ-GEF2. A Northern blot containing poly(A) mRNA from tissue of the pancreas (Pa), kidney (Ki), smooth muscles (Sm), liver (Li), lung (Lu), placenta (Pl),
brain (Br) and heart (He) was probed with a PDZ-GEF2 sequence, spanning the catalytic domain.
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proteins were incubated with different small GTPases
loaded with mantGDP, in the presence of an excess of
unlabeled GDP. Exchange activity was measured in real
time as a decrease in fluorescence. PDZ-GEF2 clearly
showed exchange activity towards both Rap1 and Rap2,
but not to H-Ras or RalA (Fig. 2A). Also, no effect of
PDZ-GEF1 and 2 on N-Ras was observed (data not
shown). The catalytic activities were quantified as reaction
rates calculated from fitted single exponential curves and
compared to the intrinsic GTPase activities. PDZ-GEF2,
like PDZ-GEF1, increased nucleotide exchange several
hundred-folds and was slightly more active towards Rap2
than to Rap1 (Fig. 2B) [12]. From these results, we
conclude that in vitro, both PDZ-GEF1 and 2 are GEFs
for Rap1 and Rap 2, but not for Ras.
3.3. PDZ-GEF2 does activate Rap1 in vivo, but not Ras
NIH-3T3-A14 cells were transiently transfected with
increasing amounts of HA-tagged PDZ-GEF1, PDZ-GEF2A
or PDZ-GEF2A-DRCBD (Fig. 3A) together with HA-tagged
Rap1A. Activation of HA-Rap1 was measured using GST-
RalGDS-RBD as an activation-specific probe [25]. All the
PDZ-GEF constructs used were able to activate Rap1 in
vivo in a concentration dependent manner (Fig. 3B). To
further study the regulation of Rap1 and possibly Ras by
PDZ-GEF1 and 2, we constructed Rat1 and NIH-3T3-A14
cell lines stably expressing different PDZ-GEF constructs,
i.e. full-length PDZ-GEF1, PDZ-GEF2-DC, PDZ-GEF1-
DRCBD-DC and PDZ-GEF2-DRCBD (Fig. 3A). Strikingly,
the cell lines expressing a PDZ-GEF construct lacking the
RCBD domain (PDZ-GEF1-DRCBD-DC and PDZ-GEF2-
DRCBD) were unstable. Analysis of a number of Rat1 cells
expressing full-length PDZ-GEF1 did not show enhanced
Rap1 activity (Fig. 3C). Similar results were obtained for
PDZ-GEF1 expressing NIH-3T3-A14 cells (data not
shown). These results suggest that full-length PDZ-GEF1,
when stably expressed, is normally inactive. Interestingly,
cells expressing PDZ-GEF2-DC did show elevated levels of
Rap1-GTP (Fig. 3D), raising the possibility that the C-
terminus might play an inhibitory role in the regulation of
catalytic activity.
The cell lines stably expressing PDZ-GEF1 were used to
investigate whether extracellular stimuli or second messen-
gers could enhance PDZ-GEF activity. However, using EGF
or endothelin, two known activators of Rap1 [3], we did not
detect more Rap1-GTP in cells expressing full-length PDZ-
GEF1 compared to the parental cell line (data not shown).
Since it was previously reported that PDZ-GEF1 is respon-
sive to cAMP with respect to Ras activation, we measured
this effect using forskolin to activate adenylate cyclase.
However, forskolin did not cause activation of Ras, but as
expected, did induce CREB phosphorylation (Fig. 3E). Also
in transient transfection experiments, using full-length PDZ-
GEF1, Rap1 was not further activated upon stimulation with
cAMP (data not shown).
3.4. RCBD of PDZ-GEF1 and 2 did not respond to cAMP
or other small molecules
To further investigate whether PDZ-GEF is responsive
to cAMP, we measured the effect of cyclic nucleotides on
PDZ-GEF activity in vitro. However, neither cAMP nor
8-Br-cGMP was able to stimulate PDZ-GEF2 catalytic
activity towards Rap2 or H-Ras. Both Rap2 and H-Ras
could be activated in this type of assay, as shown in Fig.
2A. In contrast, Epac1-DDEP, which shows hardly any
activity towards Rap2 by itself, was strongly stimulated
by cAMP (Fig. 4C). From these and previous results with
Fig. 2. In vitro activation of Rap1 and Rap2 by PDZ-GEF2. (A) Release of
mantGDP from the loaded small GTPases, measured in vitro in real time in
the presence or absence of exchange factors. The intrinsic activity of the
relevant small GTPases (black dots) and the activity of PDZ-GEF2-
DRCBD-DC towards the GTPase (open circles) are shown. As a control,
Rap1 was incubated with Epac1-DDEP in the presence of cAMP, Rap2
with PDZ-GEF1-DRCBD-DC, H-Ras with CalDAGGEF3 and RalA with
EDTA (open triangles). (B) Reaction rates for panel A are given for fitted
curves for Rap1 and Rap2 together with PDZ-GEF, and the fold induction
was calculated.
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PDZ-GEF1 [12], we conclude that in vitro, both PDZ-
GEFs are unresponsive to cAMP. To further corroborate
these findings, we determined the affinity of the RCBD of
PDZ-GEF1 for cAMP in comparison to the cAMP-bind-
ing domain of Epac1 (Fig. 5). For PDZ-GEF1 the affinity
was is in the mM range, whereas for Epac the affinity
was in the AM range. Since the 1 mM affinity is very
unlikely to be physiologically relevant, we conclude that
cAMP is not a binding partner for the RCBD of PDZ-
GEFs.
A large part of the RCBD of PDZ-GEF is very
homologues to the Epac cAMP-binding domain, with the
notable exception of cAMP interacting amino acids (Fig.
1C). It may be that other, perhaps cAMP-like, second
messengers can interact with the RCBD and activate PDZ-
GEF. We therefore tested several different nucleotides in
the in vitro assay using GST-PDZ-GEF1-DC (Fig. 3A) and
Rap2A-mantGDP. However, AMP, ADP, GDP, ATP, GTP,
ADP-ribose, cyclic ADP-ribose, h-NAADP, adenine,
adenosine and guanosine did not affect PDZ-GEF1 activity
(Fig. 4D, data not shown and Ref. [12]). To more
generally test second messengers for their ability to acti-
vate PDZ-GEFs, Jurkat T cells were stimulated with lip-
opolysaccharide (LPS) or the phorbolester TPA, both
known to activate Rap1. Extracts containing molecules
smaller than 3 kDa were used in the assay in vitro. No
effect was observed on PDZ-GEF1 activity (Fig. 4E).
Also, lysates from fMLP-stimulated neutrophils did not
affect PDZ-GEF activity (data not shown). In contrast, a
similar extract from forskolin-stimulated Jurkat cells did
stimulate Epac1-DDEP, most likely due to the presence of
cAMP (Fig. 4F), while lysates of cells stimulated by for
instance serum did not stimulate Epac1 activity (data not
shown).
3.5. The RCBD of PDZ-GEF2 is in vitro not auto-inhibitory
Previously, it was shown that the cAMP-binding domain
of Epac clearly plays an inhibitory role, which is released in
the presence of cAMP [7,9]. Besides, it was shown that PDZ-
GEF1-DC in vitro is less active than PDZ-GEF1-DRCBD-
DC and that the PDZ-GEF1-DRCBD-DC protein could be
Fig. 3. Activation of Rap1 and Ras in vivo by PDZ-GEF1 and 2A. (A) Schematic drawing of PDZ-GEF constructs that were used in the different experiments.
(B) NIH-3T3-A14 cells were transfected with HA-tagged constructs as indicated. HA-Rap1 activation (HA-Rap1-GTP) is shown, measured using RalGDS-
RBD as an activation specific probe. Total levels of transfected proteins were visualized. (C) Activity of stable expressed full-length PDZ-GEF1 in Rat1 cells
on endogenous Rap1. C stands for control and P1–3, -5, -6 and -9 are different Rat1 clones, stably expressing PDZ-GEF1. (D) PDZ-GEF2-DC, stably
expressed in NIH-3T3-A14 cells (clone P2-DC-9), activity towards Rap1, compared to the parental cell line (C). (E) A Rat1 cell line, stably expressing PDZ-
GEF1, and a control cell line were stimulated with forskolin (F) and EGF for the indicated time scales. Ras activation (Ras-GTP) is shown, measured using
Raf-RBD as an activation specific probe. The amount of phosphorylated CREB upon stimulation in the same protein samples was visualized as a control.
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inhibited by the cAMP-binding domain of Epac1 [9,12].
Based on these previous experiments, we predicted an auto-
inhibitory role for the RCBD of PDZ-GEF2. As shown by
the calculated reaction rates, deletion of the RCBD had only
a minor effect on the activity of the protein (Fig. 6A). In
agreement with this, the GST-PDZ-GEF2-DRCBD-DC pro-
Fig. 4. Role of second messengers in PDZ-GEF activation. MantGDP
loaded small GTPases were in vitro incubated with PDZ-GEF1-DC, 2-DC
or Epac1-DDEP in the presence or absence of second messengers. Intrinsic
GTPase activity is shown by black triangles (A, B). Black dots indicate the
activity of the exchange factor alone towards the GTPase. Open circles,
triangles and squares show the activity of the exchange factor in the
presence of the second messengers as indicated below. (A, B) Respectively,
Rap2A and H-Ras activation by PDZ-GEF2-DC in the presence of cAMP
(open circles) or 8Br-cGMP (open triangles). (C) Rap2A activation by
Epac1-DDEP in the presence of cAMP. (D) Rap2A activation by PDZ-
GEF1-DC in the presence of AMP (open circles), cADP-ribose (open
triangles) or h-NAADP (open squares). (E, F) Rap2A activation by,
respectively, PDZ-GEF1-DC and Epac1-DDEP in the presence of
molecules smaller than 3 kDa from Jurkat T cell lysates. Lysates from
non-stimulated cells (black dots) were added in both cases and lysates from
cells stimulated for 5 min with LPS (open triangles) or TPA (open squares)
were added (E) and lysates from cells stimulated for 10 min with forskolin
(open circles) were added (F).
Fig. 5. Affinity of the PDZ-GEF1-RCBD for cAMP. The affinities of the
isolated RCBD domain of PDZ-GEF1 (A) and the cAMP-binding domain
of Epac1 (B) were determined by ITC. The upper parts of the graphics show
the time-dependent heating power detected after each injection of cAMP. In
the lower parts, the integrated heating power is normalised to the
concentration of injected cAMP and plotted against the molar ratio of the
nucleotide and the protein. (C) Calculated Kds from the graphics above are
plotted in a table.
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tein (Fig. 3A) could not be inhibited by the cAMP-binding
domain of Epac1, or by the PDZ-GEF2-RCBD (Fig. 6B). We
conclude from this that the influence of the RCBD on the
activity of PDZ-GEF1 and 2 is different.
4. Discussion
Here we describe the identification of two splice variants
(2A and 2B) of a new PDZ-GEF family member, PDZ-GEF2.
Like PDZ-GEF1 [12], PDZ-GEF2 is a guanine nucleotide
exchange factor specific for Rap1 and Rap2. PDZ-GEF2
differs from PDZ-GEF1 in that it contains an N-terminal
extension that has a distant similarity to the RCBD of PDZ-
GEF1. This region is conserved in the single orthologue of
PDZ-GEF in C. elegans (Ce-RA-GEF [13]) (Fig. 1D).
Another difference resides in the RA domains, since the
RA domain of PDZ-GEF1 interacts with GTP-bound Rap1,
whereas the RA domain of PDZ-GEF2 interacts with GTP-
bound M-Ras [16,20]. The main differences between the
PDZ-GEF2 isoforms are found at the C-terminus. PDZ-
GEF2B lacks the proline-rich region and the PDZ binding
motif, which are present in PDZ-GEF2A and PDZ-GEF1.
Recently a third splice variant of PDZ-GEF2, RA-GEF-2,
was identified [20]. This splice variant has small additional
sequences just upstream of the RA domain and at the end of
the GEF region, but it lacks the proline-rich region of PDZ-
GEF2A (Fig. 1A and B). These differences between the
splice variants might be important for subcellular localisation
and stability. For example, both PY motifs in the proline-rich
region of PDZ-GEF2A may function as Nedd4 binding sites.
For PDZ-GEF1 it has been reported that the E3 ligase Nedd4
regulates its degradation, by binding to these sites [19].
Second, the PDZ binding motif at the C-terminus, which is
absent in PDZ-GEF2B, can bind to a PDZ domain of S-
SCAM (or MAGI-2) and MAGI-1, resulting in a location at
sites of cell–cell contact [14,17]. This localisation may have
an inhibitory effect on the activity of PDZ-GEFs since in
general PDZ-GEFs lacking the C-terminus have a higher
activity than full-length PDZ-GEFs (Fig. 3D). The RA
domain is another part of PDZ-GEF1 that was found to
influence the activity of PDZ-GEF1 [16]. Surprisingly, we
did not find elevated PDZ-GEF activity upon EGF and
endothelin stimulation in cell lines expressing PDZ-GEF1.
Since it is known that both stimuli activate Rap1, which can
bind to the RA domain of PDZ-GEF1, it appears that GTP
loaded Rap1 is not sufficient to activate this exchange factor.
Indeed, in vitro Rap1 could also not activate PDZ-GEF1,
although the RA domain in vivo was required for optimal
activity [16]. This suggests that either another small GTPase
may activate PDZ-GEF1 via the RA domain, or that an
additional signal is required.
One intriguing but controversial issue is the function of the
RCDB in PDZ-GEFs. This domain is closely related to the
cAMP-binding domain of Epac, PKA and cyclic nucleotide
gated ion channels. However, residues that are critically
involved in cAMP binding in PKA, like the ‘PRAAT’
sequence, are lacking (Fig. 1C). This suggests that PDZ-
GEFs do not bind cAMP (or cGMP). Indeed, we and others
did not find any evidence for the regulation of PDZ-GEFs by
cAMP in vitro, or in vivo [12–14], (this study). Here we
demonstrate by direct affinity measurements using isother-
mic calorimetry that the affinity of the RCDB of PDZ-GEF1
for cAMP is too low to be physiologically relevant (Fig. 5).
This result is at variance with observations by Pham et al. who
suggested that PDZ-GEF1 (CNrasGEF) mediates cAMP-
induced Ras activation through direct binding of cAMP to
PDZ-GEF1. Activation of Rap1 however was not induced by
Fig. 6. Effect of the RCBD on PDZ-GEF2 activity in vitro. (A) Catalytic
activity of PDZ-GEF2-DC (open triangles) and PDZ-GEF2-DRCBD-DC
(open squares) measured in vitro as release of mantGDP from Rap1A.
Intrinsic Rap1 activity is shown by black dots. Fold inductions were
calculated from reaction rates of the fitted curves and plotted in a table. (B)
Catalytic activity of PDZ-GEF2-DRCBD-DC (black triangles) measured as
in panel A in the presence of 15-fold excess in molar concentrations of the
PDZ-GEF2-RCBD (open triangles) or the Epac1 cAMP-binding domain
(open squares). Fold inductions were calculated from reaction rates of the
fitted curves and plotted in a table.
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cAMP in their experiments. Strikingly, in the same study, no
effect of cAMPwas observed in vitro on the activation of Ras
by immuno-precipitated PDZ-GEF1. This and our results
indicate that indeed PDZ-GEFs are not responsive to cAMP
and that the reported effect on Ras is indirect.
We previously hypothesised that the RCBD of PDZ-
GEF1 has an auto-inhibitory function, which would be
relieved by an unidentified second messenger [12]. This
was based on analogy to Epac, in which the cAMP-binding
domain is clearly an auto-inhibitory domain that completely
blocks Epac activity in vitro. Only in the presence of cAMP
or after deletion of the cAMP-binding domain, Epac is active
[7,9]. For PDZ-GEF1 it was found that the RCBD has some
inhibitory effect [12]. However, we have not been able to
identify a second messenger that could enhance the activity
of the RCBD-containing protein (Fig. 4). Furthermore,
deletion of the RCBD from our PDZ-GEF2 protein did not
significantly affect its in vitro activity (Fig. 6). Together,
these data indicate that the RCBD does not function as an
inhibitory domain. On the other hand, it should be realised
that our studies in tissue culture cells still support our initial
hypothesis. Of note, we completely failed to isolate cell lines
stably expressing PDZ-GEF-DRCBDs, although we could
easily establish cell lines expressing full-length PDZ-GEF1.
Moreover, full-length PDZ-GEF1 expressing cell lines did
not show any enhanced Rap1 activity. To our knowledge, no
other stable cell lines expressing activated RapGEFs have
been reported. This suggests that cells cannot support highly
active PDZ-GEFs and select against it. This may imply that
the RCBD requires an additional protein for its regulation.
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